Kalaris Therapeutics, Inc.
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for prevalent retinal diseases with significant unmet medical needs. The company's website is www.kalaris.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Kalaris Therapeutics, Inc. does
In the company’s own words
Kalaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing treatments for prevalent retinal diseases with significant unmet medical needs. The company's website is www.kalaris.com.
Kalaris was formed through the March 2025 merger of AlloVir, Inc. and Legacy Kalaris Tx, Inc., with Legacy Kalaris's business becoming the primary focus of the combined entity. The company is developing TH103, a novel anti-vascular endothelial growth factor (VEGF) drug engineered to achieve extended intraocular retention with enhanced VEGF inhibition for patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein functioning as a VEGF trap, leveraging molecular properties of the human body's native VEGF receptor 1.
The company is investigating TH103 as a treatment for neovascular age-related macular degeneration (nAMD), a leading cause of blindness affecting an estimated 1.6 million adults in the United States. In December 2025, Kalaris reported positive initial data from its Phase 1a single ascending dose trial in treatment-naïve nAMD patients, demonstrating that TH103 was generally well tolerated and exhibited improvements in functional and anatomical outcomes. The company is currently conducting a Phase 1b/2 multiple ascending dose study to assess safety and efficacy of repeat TH103 administration, with preliminary data expected in the first half of 2027. Assuming successful trial completion, the company intends to initiate Phase 3 clinical trials by year-end 2027.
The anti-VEGF market for retinal diseases represented an estimated fifteen billion dollars in global branded revenue during 2024. Kalaris plans to expand TH103 development beyond nAMD into other prevalent VEGF-mediated retinal diseases including diabetic macular edema, diabetic retinopathy, and retinal vein occlusion. The company's management team and board include experienced pharmaceutical executives and scientists with deep expertise in anti-VEGF therapeutic development and ophthalmology, including the scientific founder who co-discovered VEGF and was involved in developing approved anti-VEGF therapeutics. Samsara BioCapital, LP is the company's principal stockholder, beneficially owning greater than fifty percent of outstanding shares.
Company details
- Sector
- Health Care
- Industry (SIC)
- Biological Products
- Headquarters
- BERKELEY HEIGHTS, NJ
- Fiscal year end
- December
- CIK
- 1754068
- SIC
- 2836
Financial performance, year by year
Fiscal 2020–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Kalaris Therapeutics, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Kalaris Therapeutics, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Kalaris Therapeutics, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Kalaris Therapeutics, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Kalaris Therapeutics, Inc.'s last four quarterly filings that the numbers alone won't show?”